



EOS imaging announces a Corporate Agreement with the Shriners Hospitals for Children

Facilitates acquisition process of the EOS® System throughout Shriners' network of 22 pediatric hospitals

Paris, February 3, 2015 – EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in orthopedic 2D/3D imaging, announced today a corporate agreement with Shriners Hospitals for Children to facilitate the acquisition process of the EOS® System throughout the Shriners network of pediatric hospitals in North America. The EOS® System is currently in use at four Shriners hospitals within the network, and the new agreement will streamline the process for all Shriners hospitals to acquire the EOS® System and related service contracts.

Shriners Hospitals is renowned globally for its leadership in pediatric orthopedics, which addresses a full range of orthopedic conditions including scoliosis, lower limb deformities, hip dysplasia, and juvenile idiopathic arthritis, among others conditions. The network also provides advanced services for complex conditions such as spinal cord injuries .

The agreement between EOS imaging and Shriners Hospitals simplifies the process by which hospitals in the network can acquire the EOS® System through the standardization of activities surrounding corporate approvals, pricing and the establishment of pre-approved terms and agreements.

Marie Meynadier, CEO of EOS imaging, said, *“We are excited to partner with Shriners to bring the unique capabilities of the EOS System to pediatric patients across North America. This agreement builds upon the positive experience at the four sites within the Shriners network that already operate with EOS’ low-dose, 2D/3D imaging technology. We look forward to working closely with the several other sites in the network that wish to get equipped.”*

The EOS® system provides full-body stereoradiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Available) of radiation reduction by bringing pediatric spine follow up exams at the dose level equivalent to a week of natural background radiation on Earth.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit <http://www.eos-imaging.com/>.

EOS imaging has been chosen to be included in the new EnterNext® PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 47 countries,



including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

Next press release: annual results for 2014 and turnover for the 1st quarter of 2015: on April 20, 2015 (after market).



Contacts:

Anne Renevot

CFO

Ph: +33 (0)1 55 25 61 24

investors@eos-imaging.com

NewCap

Financial communication and investor relations

Antoine Denry / Pierre Laurent

Ph: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr

The Ruth Group (US)

Press relations / Melanie Sollid-Penton

Ph: 646-536-7023

msollid@theruthgroup.com